Ultragenyx Pharmaceutical Inc. (RARE) Form 8-K — Nov 3, 2026
$RAREForm 8-KItems 2.01, 2.02, 2.05, 9.01Filed Nov 3, 2026, 4:07 PM ET0001193125-26-445342Original filing
Ultragenyx reported Q3 2026 revenue of $173 million, up from $160 million a year ago, with the net loss narrowing to $118 million ($1.16/share) from $180 million ($1.81/share). The company reaffirmed full-year 2026 revenue guidance of $730-$760 million. The company closed the sale of its GENGLYCOS Priority Review Voucher for $210 million gross on October 30 and agreed to sell its FAYUVI PRV for $203 million, with combined net proceeds of approximately $350 million expected. 20% of the GENGLYCOS PRV proceeds go to the NIH under a 2018 patent license.
Key figures
- Revenue
- 173000000
- Guidance
- FY2026 total revenue $730M-$760M (excludes new launches); CRYSVITA $500M-$520M; DOJOLVI $100M-$110M; 2027 R&D <$350M and SG&A <$375M; full-year GAAP profitability expected in 2027
- Revenue Yoy
- 8.1% ($173M vs $160M)
- Total Assets
- 1187000000
- Cash Position
- 401000000
- Q3 2025 eps
- -$1.81
- Q3 2025 revenue
- $160M
- Q3 2025 net loss
- $180M
- Dojolvi q3 revenue
- $30M
- Evkeeza q3 revenue
- $24M
- Nine month revenue
- $523M
- Post rif workforce
- approximately 1,000 employees
- Crysvita q3 revenue
- $109M
- Mepsevii q3 revenue
- $10M
- Nine month net loss
- $395M
- Workforce reduction
- approximately 20%
- Fayuvi prv sale price
- $203M
- Restructuring charges
- $25M (Q4 2026)
- Combined prv sale price
- $413M
- Genglycos prv sale price
- $210M
- Expected net prv proceeds
- $350M
- Nih royalty on genglycos prv
- 20%
- Q3 net cash used in operations
- $43M
- Dec 2025 cash and marketable securities
- $737M
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.